Last edition
News about " Voyxact"
Otsuka's Voyxact Meets Key Phase 3 Endpoint in IgA Nephropathy Study
Otsuka presented new Phase 3 VISIONARY trial findings showing that Voyxact significantly slowed kidney function decline over two years, reinforcing its potential as a disease-modifying therapy for adults with primary IgA nephropathy.
Voyxact | 05/08/2026 | By News Bureau
Otsuka's Voyxact Phase 3 Trial Shows Long-Term Kidney Protection in IgA Nephropathy
Otsuka's Voyxact delivered significant long-term kidney function stabilization and reduced the risk of kidney failure in the Phase 3 VISIONARY trial, strengthening its potential as a disease-modifying treatment for IgA nephropathy.
Voyxact | 04/07/2026 | By News Bureau | 215
Otsuka receives FDA accelerated approval for Voyxact in adults with IgA nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the US FDA has granted accelerated approval for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
Voyxact | 27/11/2025 | By Darshana | 501
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy